During the last three decades, ultraviolet A1 (UVA1) phototherapy has emerged as a specific phototherapeutic modality with distinct modes of action and some well established indications. Atopic dermatitis, localized scleroderma, and systemic lupus erythematosus seem to be the conditions with the best evidence regarding efficacy and safety of UVA1 phototherapy. Further indications for UVA1 include subacute prurigo, lichen sclerosus, dyshidrotic dermatitis, cutaneous T cell lymphoma, urticaria pigmentosa, and pityriasis rosea; nevertheless, there are some unknowns, uncertainties, and controversies concerning short- and long-term side effects, efficacy and dosage regimens of UVA1 phototherapy in some conditions. We describe and discuss treatment regimens, protocols, dosage, and indications for UVA1 phototherapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clindermatol.2013.01.011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Low-Dose UVA-1 Phototherapy Treatment for Hand Eczema: A Safety and Effective Treatment.
Photodermatol Photoimmunol Photomed
January 2025
Hospital Universitario Clínico San Cecilio, Granada, Spain.
Efficacy and Safety of UVA1 Phototherapy Adjunct Treatment for Acute Cutaneous Inflammations and Neuralgia of Herpes Zoster: A Prospective, Randomized, Open-Label, Blinded End-Point Study.
Photobiomodul Photomed Laser Surg
January 2025
Department of Dermatology, Southwest Hospital, Army Medical University, Chongqing, China.
Previous case reports hint ultraviolet A1 (UVA1) phototherapy as a novel adjunct treatment for acute cutaneous inflammations and neuralgia of herpes zoster, but its clinical effectiveness and safety in this condition are not yet proven by clinical trials. To determine the efficacy and safety of UVA1 phototherapy as an adjunct treatment for acute inflammation and neuralgia in herpes zoster. A total of 60 patients with moderate-to-severe acute herpes zoster were randomly divided into two parallel groups.
View Article and Find Full Text PDFAdvancing in the Role of Low-Dose UV-A1 Phototherapy in the Treatment of Scleredema. Report on Three Cases and Literature Review.
Photodermatol Photoimmunol Photomed
January 2025
Department of Dermatology, San Cecilio University Hospital, Granada, Spain.
Phototherapy for the treatment of cutaneous graft-versus-host disease: A systematic review.
Photodermatol Photoimmunol Photomed
September 2024
Department of Dermatology, Hadassah Medical Center, Hebrew University of Jerusalem, The Faculty of Medicine, Jerusalem, Israel.
Background: Cutaneous graft-versus-host disease (GVHD) is a common complication of allogeneic hematopoietic stem cell transplantation. Phototherapy has been used to treat cutaneous GVHD, but data on its safety and efficacy are sparse.
Aim: Review the current medical literature regarding the efficacy, dosing, and safety of various types of phototherapies for the treatment of cutaneous GVHD.
Carcinogenic risk in patients treated with UVA-1 phototherapy: A 5-year retrospective study.
Photodermatol Photoimmunol Photomed
May 2024
Department of Medical, Surgical and Neurological Science, Dermatology Section, S. Maria alle Scotte Hospital, University of Siena, Siena, Italy.
Background: UVA-1 phototherapy was first used to treat atopic dermatitis and afterwards to several other skin diseases. The contribution of UVA-1 in human photocarcinogenesis, skin photoaging, immune suppression, and hyperpigmentation is now well established. The actual contribution of UVA-1 radiation to the development of malignant melanoma (MM) in humans cannot be excluded.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!